

AMENDMENTS

Listing of Claims:

1. (Original) A single chain antibody that specifically binds to an HSV glycoprotein.
2. (Original) The single chain antibody of claim 1, wherein the HSV glycoprotein is HSV glycoprotein D (HSV gD).
3. (Original) The single chain antibody of claim 1, further comprising a transmembrane region of a cell surface receptor.
4. (Original) The single chain antibody of claim 3, wherein the cell surface receptor is a T-cell receptor.
5. (Original) The single chain antibody of claim 1, wherein the single chain antibody binds site VII or site Ib of HSV gD.
6. (Original) The single chain antibody of claim 1, coupled to a second antibody that binds to an HSV glycoprotein or other pathogen associated protein.
7. (Original) The single chain antibody of claim 6, wherein the antibody is a bi-specific antibody.
8. – 11. (Canceled)
12. (Previously presented) A composition comprising the single chain antibody of claim 1.
13. (Original) The composition of claim 12, further comprising at least a second single chain antibody with a binding affinity for a pathogenic microbe that causes a sexually transmitted disease.
14. (Original) The composition of claim 13, wherein binding of the the second single chain antibody to the microbe reduces the infectivity of the microbe.

15. (Original) The composition of claim 14, wherein the microbe is HIV, HSV, chlamydia, or Hepatitis B virus.
16. (Original) The composition of claim 12, wherein the composition is comprised in a pharmaceutically acceptable composition.
17. (Original) The composition of claim 12, further comprising an antiviral therapeutic agent.
18. (Original) The composition of claim 17, wherein the antiviral therapeutic agent is a nucleoside analog.
19. (Original) The composition of claim 16, wherein the pharmaceutically acceptable composition is a topical composition.
20. (Previously presented) The composition of claim 19, wherein the topical composition is a foam or gel.
21. (Canceled)
22. (Original) The composition of claim 1, further comprising at least a second antibody.
23. – 27. (Canceled)
28. (Withdrawn) A method of producing an HSV single chain antibody comprising:
- introducing into a cell an expression cassette encoding the single chain antibody of claim 1; and
 - isolating the single chain antibody expressed by the cell.
29. (Withdrawn) The method of claim 28, wherein isolating the single chain antibody comprises purifying the single chain antibody.
30. (Withdrawn) The method of claim 29, wherein purifying the single chain antibody comprises affinity purification.
31. – 35. (Canceled)

36. (Withdrawn, currently amended) A method of preventing or treating an HSV infection comprising administering to a subject a pharmaceutically acceptable composition comprising at least a first single chain antibody of claim 1 that specifically binds a HSV glycoprotein.

37. (Withdrawn) The method of claim 36, wherein the first single chain antibody binds an epitope in a HSV glycoprotein.

38. (Withdrawn) The method of claim 37, wherein the HSV glycoprotein is HSV gD.

39. (Withdrawn) The method of claim 36, further comprising determining the subject was exposed to HSV.

40. (Withdrawn) The method of claim 36, wherein the proteinaceous composition further comprises at least a second single chain antibody having a binding specificity for at least a second microbe.

41. (Withdrawn) The method of claim 40, wherein at least a second microbe is HSV, HIV, chlamydia, or HepB.

42.– 45. (Canceled)

46. (Withdrawn, currently amended) A method for determining the presence of HSV in a sample suspected of containing HSV, the method comprising exposing the sample to a single chain antibody of claim 1 that binds an HSV glycoprotein.

47. (Withdrawn) The method of claim 46, wherein the HSV glycoprotein is HSV gD.